2025 PSMA and Beyond Conference
Date
Type
Time Duration
This two-day conference from March 28-29, 2025 is designed to facilitate a comprehensive knowledge exchange of current and future PSMA PET imaging and radioligand therapies. Delivered by distinguished faculty and international thought leaders, the conference program aims to provide an in-depth view of these imaging and therapy approaches for medical oncologists, nuclear medicine physicians, urologists, radiologists, technologists, and advanced practice providers involved in the management of prostate cancer patients. Key topics include:
- PSMA PET Imaging: We will delve into the intricacies of interpreting and reporting PSMA PET imaging, along with an evaluation of the current data supporting its use and its implications for patient care.
- PSMA-Targeted Radioligand Therapy: Gain insights into patient selection criteria and the optimal management of PSMA-targeted radioligand therapy.
- Combination Therapy and Future Trials: A critical review of the roles of combination therapy, the potential impact of ongoing and upcoming clinical trials, and the importance of dosimetry.
- Tumor Boards: Our sessions will utilize tumor boards to spotlight the pivotal role of PSMA imaging and therapy in the context of prostate cancer patients.
This two-day conference from March 28-29, 2025 is designed to facilitate a comprehensive knowledge exchange of current and future PSMA PET imaging and radioligand therapies. Delivered by distinguished faculty and international thought leaders, the conference program aims to provide an in-depth view of these imaging and therapy approaches for medical oncologists, nuclear medicine physicians, urologists, radiologists, technologists, and advanced practice providers involved in the management of prostate cancer patients. Key topics include:
- PSMA PET Imaging: We will delve into the intricacies of interpreting and reporting PSMA PET imaging, along with an evaluation of the current data supporting its use and its implications for patient care.
- PSMA-Targeted Radioligand Therapy: Gain insights into patient selection criteria and the optimal management of PSMA-targeted radioligand therapy.
- Combination Therapy and Future Trials: A critical review of the roles of combination therapy, the potential impact of ongoing and upcoming clinical trials, and the importance of dosimetry.
- Tumor Boards: Our sessions will utilize tumor boards to spotlight the pivotal role of PSMA imaging and therapy in the context of prostate cancer patients.
Speakers
